Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial

Human Psychopharmacology

Volumn 25, Issue 7-8, 2010, Pages 570-576

  Riahi, Forough ^a   Tehrani Doost, Mehdi ^b,c   Shahrivar, Zahra ^b   Alaghband Rad, Javad ^b,d  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE FOR COGNITIVE SCIENCE STUDIES   (Iran)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

adult ADHD; efficacy; reboxetine; SNRI

Indexed keywords

PLACEBO; REBOXETINE;

ABDOMINAL PAIN; ACNE; ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONNER ADULT ADHD RATING SCALE SELF REPORT SCREENING VERSION; CONSTIPATION; DIAPHORESIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EMOTIONAL DISORDER; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; IRRITABILITY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; URINE RETENTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MORPHOLINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 79951745327     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1158     Document Type: Article

References (43)

1. Alder LA,. 2004. Clinical presentation of adult patients with ADHD. J Clin Psychiatry 65 (suppl 3): 8-11.
2. Arabgol F, Panaghi L, Hebrani P,. 2009. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 18 (1): 53-60.
3. Banaschewski T, Roessner Y, Dittman RW, et al., 2004. Non-stimulant medication in the treatment of ADHD. Eur Child Adolesc Psychiatry 13 (Suppl 1): 1102-1116.
4. Belendiuk KA, Clarke TL, Chronis AM, Raggi VL,. 2007. Assessing the concordance of measures used to diagnose adult ADHD. J Atten Disord 10: 276-287.
5. Biederman J, Faraone S,. 2004. Attention-deficit/hyperactivity disorder: A worldwide concern. J Nerv Ment Dis 192 (7): 453-454.
6. Biederman J, Faraone SV, Spencer T, et al., 1993. Patterns of psychiatric comrbidity, cognition and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150: 1792-1798. (Pubitemid 23356570)
7. Biedermen J, Spencer T,. 1999. Attention deficit hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46: 1234-1242.
8. Brown TE,. 2004. Atomoxetine and stimulants in combination for treatment of ADHD. J Child Adolesc Psychopharmacol 14 (1): 129-131.
9. Cak HT,. 2006. Reboxetine use in the treatment of attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 16 (6): 803-804. (Pubitemid 46175435)
10. Chambers WJ, Puig-Antich J, Hirsch M, et al., 1985. The assessment of affective disorders in children and adolescents by semi-structured interview: Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry 42: 696-702. (Pubitemid 15054614)
11. Conners CK, Erhard D, Sparrow EP,. 1976. Conners adult ADHD rating scales (CAARS) technical manual 3rd Printing Multi Health Systems MHS, 2002. In Assessment Manual for Psychopharmacology., Guy W., (ed). U.S. Department of Health, Education and Welfare: Washington, DC.
12. Davidson MA,. 2008. ADHD in adults: A review of the literature. J Atten Disord 11: 628-641.
13. Endicott J, Spitzer RL, Fleiss IL, Cohen J,. 1976. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
14. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM,. 1999. High midbrain (18F) DOPA accumulation in children with attention deficit hyperactivity disorder. Am J psychiatry 156 (8): 1209-1215. (Pubitemid 29374881)
15. First MB, Spitzer RL, Gibbon M, Williams J,. 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version, patient Edition (SCID-I/P) New York State Psychiatric Institute, Biometric Resaerch (In Davidson): New York.
16. Guy W,. (ed). 1976. Clinical global impressions in early clinical drug evaluation unit 20. In Assessment Manual for Psychopharmacology, U.S. National Institute of Mental Health: Rockville; DHEW Publication No: [ADM]: 76-338.
17. Halperin JM, Newcorn JH, Koda VH, Pick L, Mc Kay KE, Knott P,. 1997. Noradrenergic mechanism in ADHD children with and without reading disabilities: J Am Acad Child Adolesc Psychiatry 36 (12): 1688-1697. (Pubitemid 27512323)
18. Hamilton M,. 1950. Assessment of anxiety states by rating. B. J. Med Psychol 33: 50-62.
19. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Kessler RC, Adler L, Barkley R, et al., 2006. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163: 716-723. (Pubitemid 44464584)
21. Kratochvil CJ, Heiligenstein JH, Dittimann R, et al., 2002. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective randomized open-lable trial. J Am Acad Child adolesc Psychiatry 4 (7): 776-784. (Pubitemid 38338092)
22. Kratochvil CJ, Newcorn JH, Arnold E, et al., 2005. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44: 915.
23. McGough JJ, Barkley J,. 2004. Diagnostic controversies in adult ADHD. Am J Psychiatry 161 (11): 1948-1956.
24. McGough JJ, Snalley SL, McCracken JT, et al., 2005. Psychiatric comorbidity in adults attention deficit hyperactivity disorder: Findings from multiple families. Am J Psychiatry 162: 1621-1627. (Pubitemid 41318230)
25. Michelson D, Adler L, Spencer T, et al., 2003. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53 (2): 15 Jan 112-120. (Pubitemid 36126473)
26. Michelson D, Buitelaar JK, Danckaerts M, et al., 2004. Relapse prevention in pediatric with ADHD with atomoxetine. J Am Acad Child Adolesc Psychiatry 43 (7): 896-904.
27. Michelson D, Faries D, Wernicke J, et al., 2001. Atomoxetine ADHD study group: Atomoxetine in the treatment of children and adolescent with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108 (5): E83.
28. Mozes T, Meiri G, Ben Amity G, Sabbagh M, Weizman A,. 2005. Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial. Child Adolesc Psychopharmacol 15 (2): 259-269. (Pubitemid 40734105)
29. Oades RD,. 1987. Attention deficit disorder with hyperactivity (ADDH): The contribution of catecholaminergic activity. Prog Neurobiol 29: 365-391.
30. Oades RD, Daniels R, Rascher W,. 1998. Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention deficit hyperactivity disorder. Psychiatry Res 80: 177-186. (Pubitemid 28414879)
31. Okta JE, Mercadante MT,. 2004. Reboxetine as a potentially effective treatment for ADHD. J Child Adolesc Psychopharmacol 11 (2): 203-204.
32. Plizska SR, McCracken JT, Maas JW, 1996. Catecholamine in attention deficit hyperactivity disorder: Current perspective. J Am Acad Child Adolesc Psychiatry 35: 264-272.
33. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P,. 2005. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolecse Psychiatry 44 (5): 428-433. (Pubitemid 40559690)
34. Spencer T, Biederman J, Wilens T, Harding M, O'Donnel D, Griffin S,. 1996. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 39: 409-432. (Pubitemid 126418605)
35. Tehrani Doost M, Moalemi S, Shahrivar Z,. 2008. An open label clinical trial of reboxetine in children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Pschychopharmacol 18 (2): 179-184. (Pubitemid 351591435)
36. Toren P,. 2007. Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: A long-term follow-up study. J Child Adolesc Pschychopharmacol 17 (6): 803-812.
37. Volkow ND, Wang GJ, Fowler JS, et al., 1998. Dopamine transporter occupancies in the human brain induced by therapeutic dose of oral methylphenidate. Am J Psychiatry 155: 1325-1331. (Pubitemid 28471187)
38. Wang GJ, Volkov ND, Fower JS, et al., 1995. Comparison of two PET radioligands for imaging extra striatal dopamine transporter in human brain. Life Sci 57 (14): 187-191.
39. Ward MF, Wender PH, Reimherr FW,. 1993. The Wender Utah rating scale: An aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150: 885-890. (Pubitemid 23156767)
40. Weiss M, Tannock R, Kratochvil C, et al., 2005. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44: 647.
41. Willens TE, Biederman J, Spencer TJ,. 2002. Attention deficit/hyperactivity disorder across the life span. Annu Rev Med 53: 113-131. (Pubitemid 34177874)
42. Zametkin AJ, Rapaport J,. 1986. The pathophysiology of attention deficit disorder with hyperactivity: A review. Adv Clin Child Psychol 9: 177-216.
43. Zametkin AJ, Rapaport J,. 1987. Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 26: 676-686. (Pubitemid 18016148)